TrialDiabetes care2015

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.